Research Analysts’ Recent Ratings Updates for Esperion Therapeutics (ESPR)

Several analysts have recently updated their ratings and price targets for Esperion Therapeutics (NASDAQ: ESPR):

• 10/5/2024 – Esperion Therapeutics was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 10/2/2024 – Esperion Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
• 9/27/2024 – Esperion Therapeutics was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 9/19/2024 – Esperion Therapeutics was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 9/11/2024 – Esperion Therapeutics was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 9/2/2024 – Esperion Therapeutics was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 8/22/2024 – Esperion Therapeutics was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 8/14/2024 – Esperion Therapeutics was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 8/13/2024 – Esperion Therapeutics had its price target lowered by analysts at Needham & Company LLC from $8.00 to $6.00. They now have a “buy” rating on the stock.
• 8/12/2024 – Esperion Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.

Esperion Therapeutics Price Performance

Esperion Therapeutics stock opened at $2.07 on Wednesday. Esperion Therapeutics, Inc. has a 1-year low of $0.70 and a 1-year high of $3.40. The business has a fifty day moving average price of $1.83 and a 200-day moving average price of $2.19. The stock has a market capitalization of $392.18 million, a price-to-earnings ratio of -2.09 and a beta of 1.00.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.10. The business had revenue of $73.83 million for the quarter, compared to analysts’ expectations of $51.90 million. On average, equities research analysts anticipate that Esperion Therapeutics, Inc. will post -0.04 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ESPR. Bellevue Group AG grew its holdings in shares of Esperion Therapeutics by 136.5% during the first quarter. Bellevue Group AG now owns 9,944,064 shares of the biopharmaceutical company’s stock valued at $26,650,000 after buying an additional 5,739,800 shares during the last quarter. Vanguard Group Inc. grew its stake in Esperion Therapeutics by 71.8% during the 1st quarter. Vanguard Group Inc. now owns 8,826,546 shares of the biopharmaceutical company’s stock valued at $23,655,000 after purchasing an additional 3,688,796 shares during the last quarter. Marshall Wace LLP increased its holdings in shares of Esperion Therapeutics by 94.2% in the second quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company’s stock valued at $9,554,000 after purchasing an additional 2,087,635 shares during the period. Bank of New York Mellon Corp raised its stake in shares of Esperion Therapeutics by 3,278.3% in the second quarter. Bank of New York Mellon Corp now owns 572,323 shares of the biopharmaceutical company’s stock worth $1,271,000 after purchasing an additional 555,382 shares during the last quarter. Finally, Inspire Investing LLC acquired a new stake in shares of Esperion Therapeutics during the second quarter worth about $758,000. Institutional investors and hedge funds own 47.39% of the company’s stock.

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.